Home Biotechnology Industry News
Biotechnology industry news, updates, and press releases

delta/comair travel hellI recently had the pleasure of experiencing Delta and Comair‘s friendly customer support as I attempted to make the 90 minute trip from Minneapolis to Toronto on DL 6350.

A series of mechanical failures on Delta/Comair‘s aircraft resulted in me arriving at my destination seventeen hours late. After the first flight was canceled due to mechanical problems, I had the pleasure of waiting in line for two hours to be booked into the local Radisson (an excellent hotel) by the friendly Delta team members. The generous $6 vouchers for dinner and breakfast supplied me with an excellent opportunity to experiment with caloric restriction. The next morning, as I awaited takeoff on my rebooked flight, I had ample opportunity to sleep unperturbed by turbulence as we sat on the ground waiting for the pilot ultimately scrub the flight due to the second mechanical malfunction of my trip. I had ample opportunity to contemplate the odds of two mechanical problems in a row and the implications for the safety of Delta/Comair‘s aircraft as the polite crew kept assuring us that a replacement aircraft would be available, in sequential twenty-minute increments. They were also very prompt to offer us travel vouchers after some distressed passengers loudly voiced their frustration over the extensive delay and uncertain nature of our egress. When we finally boarded a functional aircraft and were airborne, the Comair stewardess was kind enough to offer free premium beverages (valued at $5-$7), which surprisingly satiated the more vocal complainers.

It took me nearly twenty hours to complete a ninety minute flight. While I would have preferred it if Delta/Comair had rebooked me on another flight, or preferably, a more reliable airline, I did appreciate the opportunity to experience their friendly yet ineffective customer support and confidence-shaking maintenance regime. I look forward to selling my travel voucher on Ebay and finding a more reliable airline.


UPDATE

I received the following response when I submitted a formal complaint to Delta:

Thank you for contacting us.  On behalf of everyone at Delta Air Lines,  I appreciate the opportunity to be of assistance with your request.  I am truly sorry for that we are unable to go through your concern. We  recently experienced some technical problems with our online form and it appears we may not have received a portion of the information you  provided. In order to fully review your concerns, we ask that you resend your message.

So I guess that brings the number of technical problems to three!

Thank you for contacting us.  On behalf of everyone at Delta Air Lines,
I appreciate the opportunity to be of assistance with your request.
I am truly sorry for that we are unable to go through your concern. We
recently experienced some technical problems with our online form and it
appears we may not have received a portion of the information you
provided. In order to fully review your concerns, we ask that you resend
your message.

As stringent new budgets have led to pharmaceutical companies cutting back, a certain concern and scepticism has risen over the high prices charged by drug companies, their continued problems with productivity, and falling success rates of new drugs. A significant drop in investment in drugmaking companies, and president Obama’s recent reforms of the healthcare system in the USA, feel like a precursor to change in a sector that traditionally relies on older products and philosophies, rather than innovating.

In a recent issue of the Journal of Generic Medicines, world-renowned economist Joseph Stiglitz and economics professor and Roosevelt Institute fellow Arjun Jayadev examine pharmaceutical R&D from a fresh economic perspective.

Stiglitz and Jayadev put forward the argument that current models of pharmaceutical drug discovery have major inefficiencies, and suggest four different policies to address them. They propose meaningful, realistic plans and pricing models to minimise costs to the public sector, maximise positive social impact and remedy the irrationalities in the current system.

Progressive and unafraid of controversy, the article’s arguments for how to improve pharmaceutical R&D are a must-read for anyone in the industry, as well as academics, policy-makers, stakeholders and members of government.

The article is available on the Journal of Generic Medicines website.

New Reports Based on Data-Mining the DrugPatentWatch database

Please contact us with any special data requirements beyond the existing report catalog

Orphan Drug Report


The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity

The Report includes:

  • The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
  • Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
  • All FDA-listed patents covering each Orphan Drug

Report highlights:

  • More than 100 pages
  • More than 80 drugs profiled

More information is available at http://www.thinkpharm.com/orphan-drug-report.html


Drug Patent Challenge Report


The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drugs patents.

Using data on drugs approved from 2000 to 2009, this report provides complete lists of:

  • A list of the companies with the most successful patent challenges
  • A list of all the drugs for which each firm successfully challenged a patent
  • A list of all the companies that have received FDA approval for each listed drug

Report Highlights:

  • More than 60 companies profiled
  • More than 80 drugs profiled

More information is available at http://www.thinkpharm.com/drug-patent-challenge-report.html


Drug Patent Inventor Report


The Drug Patent Inventor Report profiles the individuals, US states, and countries leading pharmaceutical innovation.

Using data on drugs approved from 2000 to 2009, this report provides complete lists of:

  • Top Inventors
      Which inventors were granted the most patents?
  • Patents per Inventor
      The patents awarded to each inventor
  • Approved Drugs per Inventor
      The approved drugs protected by each inventor’s patents
  • Co-Inventors per Inventor
      The co-inventors listed on each inventor’s patents
  • Assignees per Inventor
      The assignees listed on each inventor’s patents
  • Inventors per US State
      A count of the number of inventors in each state, along with the number of patents awarded to each inventor
  • Inventors per Country
      A count of the number of inventors in each country, along with the number of patents awarded to each inventor

Data highlights

  • More than 3,000 pages
  • More than 4,000 inventors listed
  • More than 2,000 patents listed
  • 44 US states listed
  • 30 countries listed

More information is available at http://www.thinkpharm.com/drug-patent-inventor-report.html

Kraig Biocraft Laboratories, Inc. (OTC.BB:KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that scientists working in collaboration with the Company have successfully created transgenic silkworms. The silkworms were successfully genetically engineered with targeted spider silk DNA sequences.

“We are very excited to be able to announce our genetic engineering success,” said CEO Kim K. Thompson. “The creation of these transgenics was greeted with much celebration among the scientists and in the corporate office. In my view our accomplishment establishes that we have been on the right track all along. This achievement is a landmark event for the Company. It clears a major hurdle in our path and puts us well ahead of our development schedule.”

In addition to the news released today, the Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month. Earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com